The goal of this clinical trial is to investigate the role of segmentectomy in clinical T1c (2-3 cm) non-small cell lung cancer (NSCLC). The main questions we aim to answer are: 1. Is segmentectomy non-inferior to lobectomy in cT1c NSCLC in terms of overall and recurrence free survival? 2. What are the mortality and morbidity rates of segmentectomy compared to lobectomy? Researchers will compare segmentectomy and lobectomy in terms of overall and recurrence free survival. Participants will: * Undergo either pulmonary lobectomy or segmentectomy with mediastinal nodal dissection * Be followed up with a chest CT in every 3 months in first year, every 6 months in second year and every year for following 3 years
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
400
Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.
Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty
Istanbul, Turkey (Türkiye)
Survival Survival
Overall and recurrence free survival
Time frame: 5 years
Complication rate associated with surgery
Time frame: 90 days
Mortality rate
mortality rate associated with surgery
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.